1 Stock That Could Soar by 175%, According to Wall Street

• Viking Therapeutics' terms people implies a juicy upside from its existent levels.

• The stock's astir important catalysts volition apt person to hold until adjacent year.

• The drugmaker is somewhat risky, but it could present monolithic returns.

• 10 stocks we similar amended than Viking Therapeutics ›

Last twelvemonth was a challenging 1 for Viking Therapeutics (NASDAQ: VKTX), a mid-cap biotech. The institution made small objective advancement and, successful fact, 1 of the large information readouts it released was not good received by the market, starring to a sell-off. Over the trailing 12-month period, Viking Therapeutics' shares person lagged the S&P 500. But could Viking execute overmuch amended this year?

Plenty of analysts connected Wall Street deliberation so. The institution boasts an mean terms people of $93.39 (according to Yahoo! Finance), implying an upside of 175% from its existent levels. Can Viking Therapeutics soar by that overmuch successful 2026?

Viking Therapeutics' starring campaigner is VK2735, an investigational GLP-1 medicine it is processing for value management. A subcutaneous mentation of this therapy is presently successful a 78-week signifier 3 study. Viking's signifier 3 results for VK2735 volition beryllium the astir important lawsuit for the institution successful a agelong time, perchance starring to its stock terms soaring overnight, provided the results are strong.

However, considering the proceedings completed enrollment successful precocious 2025, we are improbable to spot afloat results anytime soon. The biotech volition apt uncover those successful 2027. Could we spot an interim investigation successful 2026? Maybe, but it's not clear. Viking Therapeutics is besides moving a signifier 1 attraction survey for VK2735, investigating regular oral, play oral, and monthly injection regimens successful a tiny fig of patients who person already achieved value nonaccomplishment with VK2735.

Why is this important? Losing value and keeping it disconnected are 2 antithetic things. Many GLP-1 patients regain overmuch of what they lose, and drugmakers are progressively processing strategies to assistance with that. If Viking tin amusement that continuing VK2735, successful a antithetic formulation (oral) oregon astatine antithetic intervals (monthly versus weekly), tin assistance support the value off, that would beryllium an absorbing differentiator for the medicine.

It would instrumentality a batch for Viking Therapeutics' shares to leap by 175% this year. The attraction survey is improbable to get it there, since signifier 1 studies thin to prioritize information and tolerability (things that won't importantly jolt the banal terms adjacent if they are strong) implicit efficacy. So, adjacent if this attraction survey goes well, it won't assistance Viking's shares much than treble this year.